FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078572393> ?p ?o ?g. }

• W2078572393 abstract "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, ILHyperactivation of the PI3K pathway through mutation of the PIK3CA gene, PTEN loss, or growth factor induction is prevalent in breast cancer. The use of PI3K inhibitors have recently elucidated that molecular feedbacks become active upon loss of PI3K signaling. Furthermore, PI3K activity promotes cell-cycle entry and reduces double-strand break formation. However, little is known about whether PI3K feedbacks affect DNA integrity. To study this phenomenon in a clinically applicable scenario, we developed 14 patient-derived xenografts (PDXs) from metastatic breast cancer patients enrolling in clinical trials at our institution by subcutaneous tumor implantation in female mice. A triple negative breast cancer (TNBC) model (PDX44) was characterized with a PIK3CA H1047R mutation and PTEN loss, and subsequently evaluated for response to the pan-PI3K inhibitor NVP-BKM120 at a clinically equivalent dose of 27.5mg/kg. Inhibition of PI3K led to increased DNA damage in vivo as measured by gamma H2AX foci formation or increased expression of DNA damage response genes profiled at 4 or 21 days of exposure. DNA damage was also observed with another pan-PI3K inhibitor (GDC0941; 150mg/kg) in PDX44. Furthermore, BKM120 induction of gamma H2AX foci was observed in four additional PDX models. Along with increased DNA damage response, in vivo PI3K-inhibition resulted in concomitant BRCA1 and BRCA2 loss of gene-expression. A search for putative transcriptional regulators for both BRCA1 and BRCA2 using JASPAR predicted ETS1 as a possible negative regulator of the BRCA1/2 genes. Induction of ETS1 expression following PI3K inhibition was confirmed by western blot in several PDXs. Since PI3K inhibition has been shown to induce ERK activation and ETS1 is ERK regulated, we hypothesized that PI3K regulation of BRCA1/2 is mediated by an ERK-dependent up-regulation of ETS1 upon PI3K inhibition. As a matter of fact, MEK inhibition by AZD6244 reversed the BKM120-induced increase in ETS1 and down-regulation of BRCA1/2. These data demonstrate a functional role for ERK signaling feedback up-regulation after PI3K-inhibition. Since PI3K-inhibition led to a BRCAness-like phenotype, we investigated whether synthetic lethality with simultaneous PI3K and PARP inhibition could be achieved. Whereas PDX44 showed no response to PARP inhibition alone (AZD2281/Olaparib; 50mg/kg) and partial response to PI3K inhibition as single agent (BKM120; 10 or 27.5mg/kg), concomitant PARP and PI3K blockade resulted in enhanced and prolonged antitumor activity. Therefore, PI3K-inhibition promotes synthetic lethality with a PARP inhibitor by reducing BRCA1/2 expression. Finally, as a part of the SU2C PI3K dream team, this hypothesis is being potentially investigated in clinical trials.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3746. doi:1538-7445.AM2012-3746" @default.
• W2078572393 created "2016-06-24" @default.
• W2078572393 creator A5002819777 @default.
• W2078572393 creator A5020391246 @default.
• W2078572393 creator A5021550037 @default.
• W2078572393 creator A5036020728 @default.
• W2078572393 creator A5055956240 @default.
• W2078572393 creator A5064345544 @default.
• W2078572393 creator A5077979726 @default.
• W2078572393 creator A5082756624 @default.
• W2078572393 creator A5083605021 @default.
• W2078572393 creator A5085170830 @default.
• W2078572393 creator A5087249520 @default.
• W2078572393 creator A5087308492 @default.
• W2078572393 creator A5091804771 @default.
• W2078572393 creator A5023443663 @default.
• W2078572393 date "2012-04-15" @default.
• W2078572393 modified "2023-10-17" @default.
• W2078572393 title "Abstract 3746: PI3K inhibition sensitizes to PARP inhibitors in patient-derived xenograft models of triple negative breast cancer" @default.
• W2078572393 doi "https://doi.org/10.1158/1538-7445.am2012-3746" @default.
• W2078572393 hasPublicationYear "2012" @default.
• W2078572393 type Work @default.
• W2078572393 sameAs 2078572393 @default.
• W2078572393 citedByCount "1" @default.
• W2078572393 countsByYear W20785723932019 @default.
• W2078572393 crossrefType "proceedings-article" @default.
• W2078572393 hasAuthorship W2078572393A5002819777 @default.
• W2078572393 hasAuthorship W2078572393A5020391246 @default.
• W2078572393 hasAuthorship W2078572393A5021550037 @default.
• W2078572393 hasAuthorship W2078572393A5023443663 @default.
• W2078572393 hasAuthorship W2078572393A5036020728 @default.
• W2078572393 hasAuthorship W2078572393A5055956240 @default.
• W2078572393 hasAuthorship W2078572393A5064345544 @default.
• W2078572393 hasAuthorship W2078572393A5077979726 @default.
• W2078572393 hasAuthorship W2078572393A5082756624 @default.
• W2078572393 hasAuthorship W2078572393A5083605021 @default.
• W2078572393 hasAuthorship W2078572393A5085170830 @default.
• W2078572393 hasAuthorship W2078572393A5087249520 @default.
• W2078572393 hasAuthorship W2078572393A5087308492 @default.
• W2078572393 hasAuthorship W2078572393A5091804771 @default.
• W2078572393 hasConcept C121608353 @default.
• W2078572393 hasConcept C126322002 @default.
• W2078572393 hasConcept C143425029 @default.
• W2078572393 hasConcept C182979987 @default.
• W2078572393 hasConcept C190283241 @default.
• W2078572393 hasConcept C207001950 @default.
• W2078572393 hasConcept C2777609662 @default.
• W2078572393 hasConcept C2779138821 @default.
• W2078572393 hasConcept C2780110267 @default.
• W2078572393 hasConcept C502942594 @default.
• W2078572393 hasConcept C530470458 @default.
• W2078572393 hasConcept C54355233 @default.
• W2078572393 hasConcept C552990157 @default.
• W2078572393 hasConcept C71924100 @default.
• W2078572393 hasConcept C82381507 @default.
• W2078572393 hasConcept C86554907 @default.
• W2078572393 hasConcept C86803240 @default.
• W2078572393 hasConceptScore W2078572393C121608353 @default.
• W2078572393 hasConceptScore W2078572393C126322002 @default.
• W2078572393 hasConceptScore W2078572393C143425029 @default.
• W2078572393 hasConceptScore W2078572393C182979987 @default.
• W2078572393 hasConceptScore W2078572393C190283241 @default.
• W2078572393 hasConceptScore W2078572393C207001950 @default.
• W2078572393 hasConceptScore W2078572393C2777609662 @default.
• W2078572393 hasConceptScore W2078572393C2779138821 @default.
• W2078572393 hasConceptScore W2078572393C2780110267 @default.
• W2078572393 hasConceptScore W2078572393C502942594 @default.
• W2078572393 hasConceptScore W2078572393C530470458 @default.
• W2078572393 hasConceptScore W2078572393C54355233 @default.
• W2078572393 hasConceptScore W2078572393C552990157 @default.
• W2078572393 hasConceptScore W2078572393C71924100 @default.
• W2078572393 hasConceptScore W2078572393C82381507 @default.
• W2078572393 hasConceptScore W2078572393C86554907 @default.
• W2078572393 hasConceptScore W2078572393C86803240 @default.
• W2078572393 hasLocation W20785723931 @default.
• W2078572393 hasOpenAccess W2078572393 @default.
• W2078572393 hasPrimaryLocation W20785723931 @default.
• W2078572393 hasRelatedWork W1524471987 @default.
• W2078572393 hasRelatedWork W2017755544 @default.
• W2078572393 hasRelatedWork W2025554600 @default.
• W2078572393 hasRelatedWork W2036061214 @default.
• W2078572393 hasRelatedWork W2060275594 @default.
• W2078572393 hasRelatedWork W2063195293 @default.
• W2078572393 hasRelatedWork W2093927675 @default.
• W2078572393 hasRelatedWork W2120806256 @default.
• W2078572393 hasRelatedWork W2262820072 @default.
• W2078572393 hasRelatedWork W2328459752 @default.
• W2078572393 hasRelatedWork W2330239129 @default.
• W2078572393 hasRelatedWork W2394688475 @default.
• W2078572393 hasRelatedWork W2505676185 @default.
• W2078572393 hasRelatedWork W2567383469 @default.
• W2078572393 hasRelatedWork W2599843959 @default.
• W2078572393 hasRelatedWork W2741082028 @default.
• W2078572393 hasRelatedWork W2885482630 @default.
• W2078572393 hasRelatedWork W2887884259 @default.
• W2078572393 hasRelatedWork W2943961958 @default.
• W2078572393 hasRelatedWork W2187781040 @default.
• W2078572393 isParatext "false" @default.
• W2078572393 isRetracted "false" @default.
• W2078572393 magId "2078572393" @default.

• next